Breaking News
July 22, 2018 - Survey results identify major inequalities in acute stroke treatment across Europe
July 22, 2018 - Researchers discover promising treatment for genetic form of autism spectrum disorder
July 22, 2018 - Prenatal Depression More Common in Young Moms Today
July 22, 2018 - What helps adults with autism get and keep a job?
July 22, 2018 - Pediatric NEXUS Head CT DI guides selective imaging decisions in blunt trauma patients
July 22, 2018 - Novel tool predicts genes that cause disease due to production of truncated proteins
July 22, 2018 - AHA: Vaping Tied to Blood Clots — in Mice
July 22, 2018 - Study finds therapy dogs effective in reducing symptoms of ADHD
July 22, 2018 - Scientists find reason why malarial parasites are faster than immune cells
July 22, 2018 - Researchers gain more insight into how FUS protein causes ALS and FTLD
July 22, 2018 - Frequency of joint replacements halved in rheumatoid arthritis patients between 1997-2010
July 22, 2018 - QUT researcher highlights growing impact of non-prescription antibiotics supply in pharmacies
July 22, 2018 - UK health communication researcher seeks solutions for disposing leftover medicine
July 22, 2018 - Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy Fidanacogene Elaparvovec
July 22, 2018 - Mutation discovered to protect against Alzheimer’s disease in mice
July 22, 2018 - Researchers reveal how patients in urban areas develop multiple, long-term conditions
July 22, 2018 - Replacing conventional cancer treatment with complementary therapy linked to increased risk of death
July 22, 2018 - Study uncovers molecular key for delaying progression of multiple sclerosis
July 22, 2018 - Availability of athletic trainer in high school reduces injury rates in girls’ sports, shows study
July 22, 2018 - FDA Approves Krintafel (tafenoquine) for the Radical Cure of Plasmodium vivax Malaria
July 22, 2018 - Novel nuclear medicine probe will help assess new drugs for neurodegenerative diseases
July 22, 2018 - Physical activity even during exposure to air pollution can reduce risk of heart attack
July 22, 2018 - Scientists discover protein regulator of myelin production
July 22, 2018 - Sleep disturbances associated with higher dementia risk
July 22, 2018 - Scientists move one step further in developing eye drops to treat age-related macular degeneration
July 22, 2018 - Five-Year Stroke Rates Lower After PCI Versus CABG
July 21, 2018 - Alopecia areata – Genetics Home Reference
July 21, 2018 - Study identifies overdose risk factors in youth with substance use disorders
July 21, 2018 - Drug in clinical trials for Parkinson’s disease offers hope for treating heart failure
July 21, 2018 - Coupling free malaria tests with diagnosis-dependent vouchers can improve rational use of ACTs
July 21, 2018 - Sweetness depends on molecular interactions between specific sugars and water in saliva
July 21, 2018 - Muscle fitness is strongly associated with improved rate of ageing in the brain
July 21, 2018 - Resetting E-Prescriptions for Opioids Helps Curb Use: Study
July 21, 2018 - Overuse of antibiotics not what the doctor ordered
July 21, 2018 - Bundled-payment system did not lower costs for serious medical conditions, shows study
July 21, 2018 - Therapy dogs found to be effective in reducing ADHD symptoms in children
July 21, 2018 - Could rotating multiple therapists better treat PTSD patients?
July 21, 2018 - Binge drinking impairs working memory in adolescent brain
July 21, 2018 - Dying at home could be beneficial for terminally ill cancer patients and their relatives
July 21, 2018 - Researchers identify subtypes of retinal ganglion cells using single-cell RNA sequencing
July 21, 2018 - Study uncovers opportunities to reduce death by suicide among cancer patients
July 21, 2018 - Genetic sequencing reveals new clues to aggressiveness of prostate cancer
July 21, 2018 - BioSight Launches a Phase 2b Clinical Trial of BST-236 as a First-Line Treatment of Acute Myeloid Leukemia
July 21, 2018 - First major study comparing robotic to open surgery published in The Lancet
July 21, 2018 - ADHD medications may fail to improve cognition in healthy college students, study shows
July 21, 2018 - Intervention program that includes a personalized app could benefit teens with suicidal thoughts
July 21, 2018 - Researchers identify new compound that protects against neurodegeneration
July 21, 2018 - Gene therapy may hold potential to treat people with spinal cord injuries
July 21, 2018 - FDA Approves Nivestym (filgrastim-aafi), a Biosimilar to Neupogen
July 21, 2018 - Surgeons have substantial impact on genetic testing in breast cancer patients who need it
July 21, 2018 - Species diversity can have positive and negative impacts on disease transmission
July 21, 2018 - Genome research suggests presence of enteric fever in medieval Europe
July 21, 2018 - Risk of Sensory Deficits Drops With Rising Gestational Age
July 21, 2018 - Mum’s sleep matters—the effect of sleep on an unborn baby
July 21, 2018 - UC San Diego researchers awarded two grants for investigating stem cell-based therapies
July 21, 2018 - Cellular ‘garbage disposal’ may actually work on some of the proteins to neuronal development
July 21, 2018 - More Pregnant Women Having Heart Attacks
July 21, 2018 - Acne Breakouts | NIH News in Health
July 21, 2018 - Change health messaging to focus on potential impact to help stop the next pandemic
July 21, 2018 - Frailty associated with poor survival rates in young heart patients
July 21, 2018 - New discovery could save millions of lives from fatal fungal infections
July 21, 2018 - OBD presents latest data on the use of EpiSwitch™ in predicting patient response to immunotherapy and identifying lymphoma subtypes
July 21, 2018 - Childhood adversity increases susceptibility to addiction via immune response
July 21, 2018 - Scientists identify potential target for the treatment of binge eating
July 21, 2018 - Whole-brain LIPUS therapy improves cognitive dysfunction in mice simulating dementia, Alzheimer’s
July 21, 2018 - Digital media use raising risk of ADHD symptoms among the young
July 21, 2018 - Phase 3 study of tanezumab in patients with osteoarthritis pain meets all three co-primary endpoints
July 21, 2018 - Restoring mitochondrial function to reverse aging-related skin wrinkles, hair loss in mice
July 21, 2018 - SP PennTech introduces RW-500 rotary vial washer for biotech, pharmaceutical applications
July 21, 2018 - Researchers to study molecular mechanisms behind susceptibility of males to autism
July 21, 2018 - Using tendon transfer surgery to restore key functions in spinal cord injury patient
July 21, 2018 - Scientists create wearable device that measures cortisol in sweat
July 21, 2018 - Researchers study efficacy and safety of new treatment for OUD
July 21, 2018 - Fourth Published Clinical Trial Confirms Long-Term Safety of Niagen Supplementation at High Doses and Shows Potential for Improvement in Liver Health
July 21, 2018 - Study examines effects of a two-day intermittent calorie restriction diet for patients with type 2 diabetes
July 21, 2018 - Greening vacant urban land reduces feelings of depression for surrounding residents
July 21, 2018 - Parents say intense gun violence in PG-13 movies appropriate for teens 15 and older
July 21, 2018 - Collaborative study to assess effects of exercise training for cognitive deficits in MS
July 21, 2018 - FAU researchers find possible cause of Parkinson’s disease in the patients’ immune system
July 21, 2018 - Protective qualities of ‘good cholesterol’ reduce after menopause
High-Risk Plaque No Telltale Prognosticator in Stable CAD

High-Risk Plaque No Telltale Prognosticator in Stable CAD

image_pdfDownload PDFimage_print

Action Points

  • The detection of high-risk plaque on coronary CT angiography may have only limited prognostic value among patients with stable ischemic heart disease.
  • Note that, although high-risk plaque carried a 70% increased risk of major adverse cardiovascular events, only 6.4% of patients with high-risk plaque developed MACE, while 67.2% of those who suffered an event had no high-risk plaque detected at baseline.

The detection of high-risk plaque on coronary CT angiography may have only limited prognostic value among patients with stable ischemic heart disease, researchers determined from a substudy of the PROMISE trial.

High-risk coronary atherosclerotic plaques — those with signs of positive remodeling, low CT attenuation, or napkin-ring phenomena — in people with stable chest pain were associated with more major adverse cardiovascular events (MACE) over a median 25 months of follow-up (6.4% versus 2.4% for peers without such plaques, HR 2.73, 95% CI 1.89-3.93).

That was true even after adjusting for atherosclerotic cardiovascular disease risk (ASCVD) risk score and significant stenosis (adjusted HR 1.72, 95% CI 1.13-2.62), Maros Ferencik, MD, PhD, MCR, of Oregon Health and Science University in Portland, and colleagues reported online in JAMA Cardiology.

Yet adding high-risk plaque to a risk stratification model that including ASCVD risk score and stenosis assessment did not result in a better C-index (0.69 to 0.71, P=0.12), despite better continuous net reclassification (0.34, 95% CI 0.02-0.51). Notably, only 6.4% of patients with high-risk plaque developed MACE, while 67.2% of those who suffered an event had no high-risk plaque detected at baseline.

Such a low positive predictive value associated with high-risk plaque likely precludes any clinical utility for now, Raymond Gibbons, MD, of the Mayo Clinic in Rochester, Minnesota, suggested in an invited commentary.

“Given the absence of important historical variables, electrocardiographic variables and other coronary CT angiography variables, I do not believe that the current study demonstrates that assessing high-risk plaques by coronary CT angiography is truly incremental to established risk assessment,” he wrote.

He questioned whether the reclassification was really meaningful. “[The researchers] assess the ability of a new test to move patients across these thresholds, prompting clinical actions that will hopefully improve outcomes. In the case of high-risk plaques, the potential outcomes might include more aggressive risk factor modification or invasive coronary angiography.”

“However, given the low incidence of MACE in this substudy (3.0% overall and 1.2% for hard cardiac events), it is very difficult to project that either one of these steps will improve outcomes,” he emphasized.

The prespecified nested observational cohort study by Ferencik’s group included stable, symptomatic outpatients who required noninvasive cardiovascular testing and got coronary CT angiography (n=4,415). The overall PROMISE trial randomized patients with stable chest pain to coronary CT angiography or functional testing. In the main findings, coronary CT angiography did not lead to better outcomes but increased the number of procedures done.

Significant stenosis was defined as 70% or greater stenosis in any vessel or at least 50% in the left main coronary artery. It turned out that patients with significant stenosis had similar MACE rates whether or not they had high-risk plaque.

High-risk plaque seemed to be most telling of future risk for those with nonobstructive coronary artery disease, women, and younger patients.

“Sex-based differences in plaque size and composition have been more pronounced in younger women and more attenuated in women older than 65 years. We speculate that when high-risk plaques are present in younger women, they portend a higher risk of future MACE,” according to Ferencik and colleagues.

Their PROMISE substudy led Gibbons to highlight the need to increase value and reduce waste in biomedical research.

“Novel risk markers should be rigorously evaluated before they are used routinely in clinical practice. The detection of high-risk plaques by coronary CT angiography is an appropriate subject for future research exploring the pathophysiology of plaque biology and its intersection with acute coronary syndromes,” he wrote. “However, in my opinion, the evidence is not yet strong enough for us to use it in the clinical care of patients with stable ischemic heart disease.”

The PROMISE trial was funded by National Heart, Lung, and Blood Institute grants.

Ferencik reported a grant from the American Heart Association.

Gibbons disclosed personal fees from Peer View Institute and Astellas Pharmaceuticals.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2018-01-10T11:00:00-0500

Tagged with:

About author

Related Articles